MedTrace Logo

The National Program for the Improvement of Management of Fetal Congenital Heart Disease in China

NCT05940363 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 9000

Last updated 2023-07-11

No results posted yet for this study

Summary

To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling of congenital heart disease in medical institutions in China, in order to understand the current status and existing problems of prenatal prevention and treatment capacity of congenital heart disease in China, and to obtain corresponding baseline data, so as to provide scientific basis for further improving prenatal screening and diagnosis policies in China.

Conditions

  • Congenital Heart Disease in Pregnancy
  • Prenatal Diagnosis
  • Fetal Echocardiography

Interventions

COMBINATION_PRODUCT

Improvement on Prenatal Screening and Treatment Capabilities for Congenital Heart Disease with a Comprehensive Diagnosis and Treatment Program Incorporating New Technologies

To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling for fetal heart disease based on medical institutions; Improving capacity for prenatal screening, diagnosis and counselling through integrated products embedded with new technologies.

Sponsors & Collaborators

  • Beijing Anzhen Hospital

    lead OTHER

Principal Investigators

  • Yihua He, MD · Beijing Anzhen Hospital

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2023-09-01
Completion
2026-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05940363 on ClinicalTrials.gov